@article{Imzharov_Balci_Zhakiev_Kurmangaliev_Sarkulov_Aslan_Pavlov_Lakman_Kelimberdiev_2026, place={Fidenza, Italy}, title={Evaluation of the effectiveness of dioxydin metaphylaxis of nephrolithiasis in percutaneous nephrolithotripsy}, volume={97}, url={https://mattioli1885journals.com/index.php/actabiomedica/article/view/19439}, DOI={10.23750/abm.2026.19439}, abstractNote={
Background and aim. Infectious complications and stone recurrence remain major challenges after percutaneous nephrolithotomy (PCNL) for large kidney stones. This study aimed to evaluate the effectiveness of adjunctive intracavitary 1% dioxidine administration for metaphylaxis of for reducing postoperative infectious complications and stone recurrence following PCNL. Methods. This prospective, randomized, single-blind controlled trial included 95 patients (aged 18–70 years) with kidney stones >2 cm undergoing PCNL. Patients were randomized 1:1 into control (standard systemic ceftriaxone therapy, n=48) and intervention groups (standard therapy plus intracavitary 10 ml 1% dioxidine intraoperatively and on postoperative days 1–2, n=47). Primary outcomes were bacteriuria and leukocyturia at 7 days and 3 months. Secondary outcomes included Clavien–Dindo complications, stone recurrence at 6 months (low-dose CT), laboratory parameters, and stone composition. Results. Intracavitary dioxidine significantly reduced bacteriuria at 7 days (10.6% vs 45.8%, p<0.001) and 3 months (4.3% vs 52.1%, p<0.001). Leukocyturia was markedly lower in the dioxidine group at both time points (p<0.001). Clinically significant complications (Clavien–Dindo ≥II) occurred in 4.3% vs 25.0% (p=0.004), and stone recurrence at 6 months was 4.3% vs 22.9% (p=0.008). Difference-in-Differences analysis confirmed a strong independent effect of dioxidine on urine leukocytes at 1 week (–9.24 ± 2.42, p<0.001) and 3 months (–6.52 ± 2.29, p=0.005). No adverse reactions were observed, and renal function remained stable. Conclusions. Adjunctive intracavitary 1% dioxidine during and after PCNL is a safe and effective strategy for reducing postoperative infectious complications and stone recurrence. Larger multicenter trials are warranted.
}, number={4}, journal={Acta Biomedica Atenei Parmensis}, author={Imzharov, Talgat A. and Balci, Melih and Zhakiev, Bazylbek and Kurmangaliev, Oleg and Sarkulov, Marat and Aslan, Yilmaz and Pavlov, Valentin and Lakman, Irina and Kelimberdiev, Mirsaid Saubetovich}, year={2026}, month={Aug.}, pages={19439} }